Lucid Diagnostics enters $25M ATM equity offering with Maxim Group

Lucid Diagnostics Inc.

Up to $25M of common stock may be sold at-the-market via Maxim Group as agent.
Agent commission set at 3% of gross proceeds; $60k legal fee reimbursement at signing.
Proceeds to be used for working capital and general corporate purposes.
Agreement dated May 30, 2025; offering under effective Form S-3 (File No. 333-268560).
Company may terminate agreement at any time with ten business days' notice.

item 1.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.